MacroGenics (MGNX)
(Delayed Data from NSDQ)
$14.56 USD
+0.19 (1.32%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $14.54 -0.02 (-0.14%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth A Momentum D VGM
MacroGenics (MGNX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$23.44 | $30.00 | $13.00 | 63.12% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for MacroGenics comes to $23.44. The forecasts range from a low of $13.00 to a high of $30.00. The average price target represents an increase of 63.12% from the last closing price of $14.37.
Analyst Price Targets (9 )
Broker Rating
MacroGenics currently has an average brokerage recommendation (ABR) of 1.20 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.40 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, nine are Strong Buy, representing 90% of all recommendations. A month ago, Strong Buy represented 80%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 8 | 8 | 9 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 2 | 3 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.20 | 1.20 | 1.40 | 1.55 | 1.36 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/26/2024 | B. Riley Securities | Mayank Mamtani | Strong Buy | Strong Buy |
4/3/2024 | Guggenheim Securities | Michael Schmidt | Strong Buy | Strong Buy |
3/11/2024 | JMP Securities | Silvan C Tuerkcan | Strong Buy | Strong Buy |
3/11/2024 | H.C. Wainwright & Co. | Robert Burns | Hold | Hold |
3/8/2024 | BMO Capital Markets | Etzer Darout | Strong Buy | Strong Buy |
3/4/2024 | BTIG | Kaveri Pohlman | Strong Buy | Strong Buy |
3/1/2024 | SVB Securities | Jonathan W Chang | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.20 |
ABR (Last week) | 1.20 |
# of Recs in ABR | 10 |
Average Target Price | $23.60 |
LT Growth Rate | NA |
Industry | Medical - Products |
Industry Rank by ABR | 142 of 252 |
Current Quarter EPS Est: | -0.67 |